Treatment using 5-FU activated CSCs via p53-induced WNT3 transcription, followed by the activation of the WNT/β-catenin pathway in CRC cell lines and xenograft tumors as well as patient avatar models [19]. The gene discussed is TP53; the disease is colorectal carcinoma.